Inhibrx Q3 net loss widens on higher G&A expenses

By Reuters News


Overview

  • US biopharma firm's Q3 net loss was a slight beat versus analyst estimates

  • Q3 loss per share beat analyst expectations

  • License fee revenue rose to $2 mln on Pfizer agreement


Outlook

  • Company expects initial Phase 2 readout for ordastobart (INBRX-106) in HNSCC around mid-2027

  • Company expects initial results for ordastobart (INBRX-106) in perioperative NSCLC in mid-2027

  • Commercial readiness activities for ozekibart (INBRX-109) in chondrosarcoma advancing in line with regulatory review timeline


Result Drivers

  • PFIZER LICENSE REVENUE - Co recognized $2 mln in license fee revenue from a non-exclusive license agreement with Pfizer

  • LOWER R&D COSTS - Research and development expenses fell due to decreased clinical trial costs and reduced headcount, partly offset by higher contract manufacturing expenses

  • HIGHER G&A EXPENSES - General and administrative expenses increased due to pre-commercialization activities for ozekibart

  • INCREASED INTEREST EXPENSE - Other expenses rose mainly due to higher interest expense on increased loan balance


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Loss Per Share

Beat

$2.46

$2.52 (3 Analysts)

Q3 Net Loss

Slight Beat*

$38.73 mln

$38.85 mln (3 Analysts)

Q3 Operating Income

Beat

-$31.74 mln

-$35.46 mln (3 Analysts)

Q3 License Fee Revenue

$2 mln

Q3 Operating Expenses

$33.74 mln

*Applies to a deviation of less than 1%; not applicable for per-share numbers.


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • Wall Street's median 12-month price target for Inhibrx Biosciences Inc is $245.00, about 179.2% above its November 12 closing price of $87.75


Reuters Recommended Reads

  • Nov 12 - Rocket Pharmaceuticals Q3 net loss narrows as R&D costs fall

  • Nov 13 - PDS Biotechnology Q3 net loss narrows on lower R&D costs

  • Nov 12 - Crescent Biopharma Q3 net loss widens beyond expectations on higher R&D expenses


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk